Xentria’s XTMAB-16 Receives Orphan Drug Designation From EMA
15 Nov 2023 //
BUSINESSWIRE
Meitheal pays Xentria $45M for right to TNF drug in lung disease
27 Jun 2023 //
FIERCE BIOTECH
Xentria Announces Peer Reviewed Publication of Biosimulation Model
21 Mar 2023 //
BUSINESSWIRE
Xentria Appoints Lead Scientific Advisor and Chief Operating Officer
04 Aug 2022 //
BUSINESSWIRE
Xentria Announces Initial Findings Showing Novel Biologic XTMAB-16’s Potential
23 Jun 2022 //
BUSINESSWIRE